For immediate release |
24 September 2013 |
Futura Medical plc
("Futura" or "the Company")
Grant of Options
Futura Medical plc (AIM: FUM), the innovative healthcare company focused on advanced transdermal technology, announces that on 23 September 2013 it granted options over a total of 580,000 ordinary shares of 0.2p each in the Company to Directors as detailed below.
Director |
Number of options granted |
Exercise price |
Exercise period |
Total number of options held following notification |
Total number of ordinary shares held |
|
|
|
|
|
|
J H Barder |
250,000 |
71.50p |
1 Oct 2015 - 30 Sep 2020 |
1,000,000 |
968,830 |
D B Davies |
200,000 |
71.50p |
1 Oct 2015 - 30 Sep 2020 |
800,000 |
751,306 |
D A Martin |
130,000 |
71.50p |
1 Oct 2015 - 30 Sep 2020 |
589,279 |
280,000 |
All options granted on 23 September 2013 were under the Futura Medical plc Enterprise Management Incentive Scheme with the exception of 215,385 options granted to J H Barder and 122,378 options granted to D B Davies which were granted under the Futura Medical plc Unapproved Share Option Scheme.
The main vesting condition of the options is that the Directors remain employed with the Company as at the date of exercise.
For any further information please contact:
Futura Medical plc |
|
James Barder, Chief Executive |
Tel: +44 (0)1483 685 670 |
mail to: james.barder@futuramedical.com |
|
|
|
Cenkos Securities plc |
|
Bobbie Hilliam |
Tel:+44 (0)20 7397 8900 |
|
|
For media enquiries please contact: |
|
|
|
Buchanan |
|
Mark Court / Fiona Henson / Sophie Cowles |
Tel: +44 (0)20 7466 5000 |
Notes to Editors
Futura Medical plc
Futura Medical is a pharmaceutical group that develops innovative products for consumer healthcare. The Company is developing a portfolio of products and its strategy is to license their manufacture and distribution to major pharmaceutical and healthcare groups.
Futura is based in Guildford, Surrey, and its shares trade on the AIM market of the London Stock Exchange.